AML
FDA Approves Preparative Regimen for allo-HSCT in Patients With AML or MDS
The FDA has approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative ...
FEBRUARY 19, 2025
Continuous Temperature Monitoring Could Detect Febrile Neutropenia
Remote temperature monitoring devices may enable early detection of febrile neutropenia in adults with AML who have ...
JUNE 5, 2024
Guide Identifies AML Patients at Risk for Early Treatment-Related Death
A risk stratification guide could help clinicians select the optimal intensity of chemotherapy for patients with ...
MAY 27, 2022
New Treatment OK’d for Newly Diagnosed IDH1-Mutant AML
The FDA approved the combination of ivosidenib (Tibsovo, Servier) plus azacitidine for adults aged 75 years and ...
MAY 27, 2022
HIV in Remission After U.S. Woman Receives Haplo-Cord Transplant
A middle-aged woman with HIV who received a cord blood hematopoietic cell transplant to treat acute myeloid ...
FEBRUARY 16, 2022
Maximizing the Benefit of Venetoclax in AML
The approval of venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine provides ...
AUGUST 23, 2021
For New AML, 10-Day Decitabine-Venetoclax Combo Found Effective
Treatment with a regimen of venetoclax and 10 days of decitabine resulted in a median overall survival of 18 months ...
SEPTEMBER 28, 2020
AML Rx Evolves With Growing List of Options
In acute myeloid leukemia (AML), newer options, such as a FLT3 inhibitor for relapsing-remitting disease and ...
SEPTEMBER 28, 2020
Onureg, Oral Formulation of Azacitidine, Approved for AML
The FDA granted approval to azacitidine tablets (Onureg, Celgene) for treatment of patients with acute myeloid ...
SEPTEMBER 4, 2020
FDA Expands Use of Mylotarg to Infants at Least 1 Month Old
The FDA extended the indication for gemtuzumab ozogamicin (Mylotarg, Wyeth) to treat newly diagnosed CD33-positive ...
JUNE 19, 2020
Report From ASH 2019: Oral Azacitidine Formulation Extends First Remissions in AML
ORLANDO, FLA.—A novel oral formulation of azacitidine produced a highly significant improvement in overall ...
DECEMBER 19, 2019
Gilteritinib Effective for Relapsed/Refractory FLT3-Mutated AML
Findings from the randomized, phase 3 ADMIRAL study have found the FLT3 inhibitor gilteritinib (Xospata, Astellas) ...
NOVEMBER 25, 2019
